JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating and $126.00 price target on Blueprint Medicines (NASDAQ: BPMC).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE